Request a Premium Quote Breaking News FDA Accepts BMS's NDA for Repotrectinib in ROS1-Positive NSCLC FDA Approves Blue Earth Diagnostics' PSMA-Targeted Radiohybrid PET Imaging Agent Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring In Brief This Week: Clarity Pharmaceuticals, Regenxbio, Rocket Pharmaceuticals, Eisai, AstraZeneca Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout WashU Researchers Studying Amyloid-Lowering Insomnia Drug's Effect on Alzheimer's Development
